Strategies for a comprehensive understanding of metabolism by aldehyde oxidase

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 2, 2013, Pages 153-168

  Hutzler, James Matthew ^a   Obach, Ronald Scott ^b   Dalvie, Deepak ^b   Zientek, Michael A ^b  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b PFIZER INC   (United States)

Author keywords

Aldehyde oxidase; Clearance; Drug discovery and development; Drug metabolism; in vitro; Pharmacokinetics; Toxicology

Indexed keywords

ALDEHYDE OXIDASE; CARBAZERAN; FALNIDAMOL; FK 3453; RO 1; SGX 523; UNCLASSIFIED DRUG; ZONIPORIDE;

DRUG METABOLISM; DRUG SAFETY; ENZYME METABOLISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OXIDATION; REVIEW;

ALDEHYDE OXIDASE; ANIMALS; HUMANS; METABOLIC NETWORKS AND PATHWAYS; PHARMACEUTICAL PREPARATIONS;

EID: 84872445053     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.738668     Document Type: Review

References (81)

1. Thompson TN. Early ADME in support of drug discovery: the role of metabolic stability studies. Curr Drug Metab 2000;1:215-41
2. Zhao SX, Forman D, Wallace N, et al. Simple strategies for reducing sample loads in in vitro metabolic stability high-throughput screening experiments: a comparison between traditional, two-time-point and pooled sample analyses. J Pharm Sci 2005;94:38-45 (Pubitemid 40116368)
3. Strolin BM, Whomsley R, Baltes E. Involvement of enzymes other than CYPs in the oxidative metabolism of xenobiotics. Expert Opin Drug Metab Toxicol 2006;2:895-921 (Pubitemid 44911539)
4. Beedham C. Molybdenum hydroxylases: biological distribution and substrate-inhibitor specificity. Prog Med Chem 1987;24:85-127
5. Kitamura S, Sugihara K, Ohta S. Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab Pharmacokinet 2006;21:83-98
6. Garattini E, Fratelli M, Terao M. Mammalian aldehyde oxidases: genetics, evolution and biochemistry. Cell Mol Life Sci 2008;65:1019-48
7. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes. Drug Metab Pharmacokinet 2006;21:357-74
8. Hille R. Molybdenum-containing hydroxylases. Arch Biochem Biophys 2005;433:107-16 (Pubitemid 39591630)
9. Alfaro JF, Jones JP. Studies on the mechanism of aldehyde oxidase and xanthine oxidase. J Org Chem 2008;73:9469-72
10. Al-Salmy HS. Individual variation in hepatic aldehyde oxidase activity. IUBMB Life 2001;51:249-53 (Pubitemid 32848156)
11. Sahi J, Khan KK, Black CB. Aldehyde oxidase activity and inhibition in hepatocytes and cytosolic fractions from mouse, rat, monkey and human. Drug Metab Lett 2008;2:176-83
12. Itoh K, Maruyama H, Adachi M, et al. Lack of dimer formation ability in rat strains with low aldehyde oxidase activity. Xenobiotica 2007;37:709-16 (Pubitemid 47057125)
13. Beedham C, Bruce SE, Critchley DJ, et al. Species variation in hepatic aldehyde oxidase activity. Eur J Drug Metab Pharmacokinet 1987;12:307-10 (Pubitemid 18058717)
14. Pryde DC, Dalvie D, Hu Q, et al. Aldehyde oxidase: an enzyme of emerging importance in drug discovery. J Med Chem 2010;53:8441-60
15. Garattini E, Terao M. Increasing recognition of the importance of aldehyde oxidase in drug development and discovery. Drug Metab Rev 2011;43:374-86
16. Garattini E, Terao M. The role of aldehyde oxidase in drug metabolism. Expert Opin Drug Metab Toxicol 2012;8:487-503
17. Kaye B, Offerman JL, Reid JL, et al. A species difference in the presystemic metabolism of carbazeran in dog and man. Xenobiotica 1984;14:935-45 (Pubitemid 15198638)
18. Dittrich C, Greim G, Borner M, et al. Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer 2002;38:1072-80 (Pubitemid 34468012)
19. Dalvie D, Zhang C, Chen W, et al. Cross-species comparison of the metabolism and excretion of zoniporide: contribution of aldehyde oxidase to interspecies differences. Drug Metab Dispos 2010;38:641-54
20. Zhang X, Liu HH, Weller P, et al. In silico and in vitro pharmacogenetics: p38 kinase inhibitor. Pharmacogenomics J 2011;11:15-24
21. Akabane T, Tanaka K, Irie M, et al. Case report of extensive metabolism by aldehyde oxidase in humans: pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans. Xenobiotica 2011;41:372-84
22. Diamond S, Boer J, Maduskuie TP Jr, et al. Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications. Drug Metab Dispos 2010;38:1277-85
23. Meanwell NA. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. Chem Res Toxicol 2011;24:1420-56
24. Meanwell NA. Synopsis of some recent tactical application of bioisosteres in drug design. J Med Chem 2011;54:2529-91
25. St Jean DJJ, Fotsch C. Mitigating heterocycle metabolism in drug discovery. J Med Chem 2012;55:6002-20
26. Obach RS. Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab Dispos 2004;32:89-97 (Pubitemid 38112540)
27. Puig JG, Mateos FA, Diaz VD. Inhibition of xanthine oxidase by allopurinol: a therapeutic option for ischaemia induced pathological processes? Ann Rheum Dis 1989;48:883-8 (Pubitemid 19280908)
28. van de Waterbeemd H, Smith DA, Jones BC. Lipophilicity in PK design: methyl, ethyl, futile. J Comput Aided Mol Des 2001;15:273-86 (Pubitemid 32219940)
29. Lewis DF, Dickins M. Substrate SARs in human P450s. Drug Discov Today 2002;7:918-25
30. Lewis DF, Jacobs MN, Dickins M. Compound lipophilicity for substrate binding to human P450s in drug metabolism. Drug Discov Today 2004;9:530-7 (Pubitemid 38739334)
31. Smith DA. Discovery and ADMET: where are we now. Curr Top Med Chem 2011;11:467-81
32. Linton A, Kang P, Ornelas M, et al. Systematic structure modifications of imidazo[1,2-a]pyrimidine to reduce metabolism mediated by aldehyde oxidase (AO). J Med Chem 2011;54:7705-12
33. Pryde DC, Tran TD, Jones P, et al. Medicinal chemistry approaches to avoid aldehyde oxidase metabolism. Bioorg Med Chem Lett 2012;22:2856-60 eliminating metabolism by AO.
34. Chan K, Poon R, O'Brien PJ. Application of structure-activity relationships to investigate the molecular mechanisms of hepatocyte toxicity and electrophilic reactivity of alpha, beta-unsaturated aldehydes. J Appl Toxicol 2008;28:1027-39
35. Ghafourian T, Rashidi MR. Quantitative study of the structural requirements of phthalazine/quinazoline derivatives for interaction with human liver aldehyde oxidase. Chem Pharm Bull (Tokyo) 2001;49:1066-71 (Pubitemid 32847508)
36. Dalvie D, Sun H, Xiang C, et al. Effect of structural variation on aldehyde oxidase-catalyzed oxidation of zoniporide. Drug Metab Dispos 2012;40:1575-87
37. Torres RA, Korzekwa KR, McMasters DR, et al. Use of density functional calculations to predict the regioselectivity of drugs and molecules metabolized by aldehyde oxidase. J Med Chem 2007;50:4642-7 (Pubitemid 47463238)
38. Sun H, Scott DO. Structure-based drug metabolism predictions for drug design. Chem Biol Drug Des 2010;75:3-17
39. de Groot MJ. Designing better drugs: predicting cytochrome P450 metabolism. Drug Discov Today 2006;11:601-6
40. Afzelius L, Arnby CH, Broo A, et al. State-of-the-art tools for computational site of metabolism predictions: comparative analysis, mechanistical insights, and future applications. Drug Metab Rev 2007;39:61-86
41. Dastmalchi S, Hamzeh-Mivehrod M. Molecular modelling of human aldehyde oxidase and the identification of the key interactions in the enzyme-substrate complex. Daru J Fac Pharm Tehran Univ Med Sci 2005;13:82-93 (Pubitemid 43167978)
42. Sharma R, Strelevitz TJ, Gao H, et al. Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs. Drug Metab Dispos 2012;40:625-34
43. Magee TV, Ripp SL, Li B, et al. Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections. J Med Chem 2009;52:7446-57
44. Renwick AB, Ball SE, Tredger JM, et al. Inhibition of zaleplon metabolism by cimetidine in the human liver: in vitro studies with subcellular fractions and precision-cut liver slices. Xenobiotica 2002;32:849-62 (Pubitemid 35155520)
45. Johns DG. Human liver aldehyde oxidase: differential inhibition of oxidation of charged and uncharged substrates. J Clin Invest 1967;46:1492-505
46. Hodnett CN, McCormack JJ, Sabean JA. Oxidation of selected pteridine derivatives by mammalian liver xanthine oxidase and aldehyde oxidase. J Pharm Sci 1976;65:1150-4
47. Jordan CG, Rashidi MR, Laljee H, et al. Aldehyde oxidase-catalysed oxidation of methotrexate in the liver of guinea-pig, rabbit and man. J Pharm Pharmacol 1999;51:411-18 (Pubitemid 29248317)
48. Floreani M, Carpenedo F. Inhibition of rat liver monooxygenase activities by 2-methyl-1,4-naphthoquinone (menadione). Toxicol Appl Pharmacol 1990;105:333-9 (Pubitemid 20332844)
49. Price RJ, Mistry H, Wield PT, et al. Comparison of the toxicity of allyl alcohol, coumarin and menadione in precision-cut rat, guinea-pig, cynomolgus monkey and human liver slices. Arch Toxicol 1996;71:107-11 (Pubitemid 26402876)
50. Pearson JT, Wahlstrom JL, Dickmann LJ, et al. Differential time-dependent inactivation of P450 3A4 and P450 3A5 by raloxifene: a key role for C239 in quenching reactive intermediates. Chem R
51. Obach RS, Huynh P, Allen MC, Beedham C. Human liver aldehyde oxidase: inhibition by 239 drugs. J Clin Pharmacol 2004;44:7-19
52. Shin JG, Soukhova N, Flockhart DA. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos 1999;27:1078-84 (Pubitemid 29409646)
53. Strelevitz TJ, Orozco CC, Obach RS. Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance. Drug Metab Dispos 2012;40:1441-8
54. Johnson C, Stubley-Beedham C, Stell JG. Hydralazine: a potent inhibitor of aldehyde oxidase activity in vitro and in vivo. Biochem Pharmacol 1985;34:4251-6 (Pubitemid 16204474)
55. Critchley DJ, Rance DJ, Beedham C. Biotransformation of carbazeran in guinea pig: effect of hydralazine pretreatment. Xenobiotica 1994;24:37-47 (Pubitemid 24058004)
56. Zientek M, Jiang Y, Youdim K, Obach RS. In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase. Drug Metab Dispos 2010;38:1322-7
57. Hutzler JM, Yang YS, Albaugh D, et al. Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes. Drug Metab Dispos 2012;40:267-75
58. Akabane T, Gerst N, Masters JN, Tamura K. A quantitative approach to hepatic clearance prediction of metabolism by aldehyde oxidase using custom pooled hepatocytes. Xenobiotica 2012;42:863-71
59. Duley JA, Harris O, Holmes RS. Analysis of human alcohol- and aldehyde-metabolizing isozymes by electrophoresis and isoelectric focusing. Alcohol Clin Exp Res 1985;9:263-71 (Pubitemid 15011403)
60. Moriwaki Y, Yamamoto T, Takahashi S, et al. Widespread cellular distribution of aldehyde oxidase in human tissues found by immunohistochemistry staining. Histol Histopathol 2001;16:745-53 (Pubitemid 32700384)
61. Wilkinson GR, Shand DG. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975;18:377-90
62. Sanoh S, Horiguchi A, Sugihara K, et al. Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver. Drug Metab Dispos 2012;40:322-8
63. Akabane T, Gerst N, Naritomi Y, et al. A practical and direct comparison of intrinsic metabolic clearance of several non-CYP enzyme substrates in freshly isolated and cryopreserved hepatocytes. Drug Metab Pharmacokinet 2012;27:181-91
64. Kitamura S, Sugihara K, Nakatani K, et al. Variation of hepatic methotrexate 7-hydroxylase activity in animals and humans. IUBMB Life 1999;48:607-11 (Pubitemid 30043806)
65. Hartmann T, Terao M, Garattini E, et al. The impact of single nucleotide polymorphisms on human aldehyde oxidase. Drug Metab Dispos 2012;40:856-64
66. Kestell P, Dunlop IC, McCrystal MR, et al. Plasma pharmacokinetics of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in a phase I trial. Cancer Chemother Pharmacol 1999;44:45-50 (Pubitemid 29246324)
67. Kharasch ED, Russell M, Mautz D, et al. The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. Anesthesiology 1997;87:36-50 (Pubitemid 27438621)
68. Tayama Y, Sugihara K, Sanoh S, et al. Developmental changes of aldehyde oxidase activity and protein expression in human liver cytosol. Drug Metab Pharmacokinet 2012; Epub ahead of print
69. Barr JT, Jones JP. Inhibition of human liver aldehyde oxidase: implications for potential drug-drug interactions. Drug Metab Dispos 2011;39:2381-6
70. Obach RS. Predicting drug-drug interactions from in vitro drug metabolism data: challenges and recent advances. Curr Opin Drug Discov Devel 2009;12:81-9
71. Rivera SP, Choi HH, Chapman B, et al. Identification of aldehyde oxidase 1 and aldehyde oxidase homologue 1 as dioxin-inducible genes. Toxicology 2005;207:401-9 (Pubitemid 40138937)
72. Baillie TA, Cayen MN, Fouda H, et al. Drug metabolites in safety testing. Toxicol Appl Pharmacol 2002;182:188-96
73. Smith DA, Obach RS. Metabolites and safety: what are the concerns, and how should we address them? Chem Res Toxicol 2006;19:1570-9 (Pubitemid 44975120)
74. Li Y, Xu J, Lai WG, et al. Metabolic switching of BILR 355 in the presence of ritonavir. II. Uncovering novel contributions by gut bacteria and aldehyde oxidase. Drug Metab Dispos 2012;40:1130-7
75. Huang F, Koenen-Bergmann M, MacGregor TR, et al. Pharmacokinetic and safety evaluation of BILR 355, a second-generation nonnucleoside reverse transcriptase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 2008;52:4300-7
76. Dolan ME, Roy SK, Fasanmade AA, et al. O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings. J Clin Oncol 1998;16:1803-10
77. Morrison RD, Blobaum AL, Byers FW, et al. The role of aldehyde oxidase and xanthine oxidase in the biotransformation of a novel negative allosteric modulator of metabotropic glutamate receptor subtype 5. Drug Metab Dispos 2012;40:1834-45
78. Kawashima K, Hosoi K, Naruke T, et al. Aldehyde oxidase-dependent marked species difference in hepatic metabolism of the sedative-hypnotic, zaleplon, between monkeys and rats. Drug Metab Dispos 1999;27:422-8 (Pubitemid 29114253)
79. Itoh K, Yamamura M, Takasaki W, et al. Species differences in enantioselective 2-oxidations of RS-8359, a selective and reversible MAO-A inhibitor, and cinchona alkaloids by aldehyde oxidase. Biopharm Drug Dispos 2006;27:133-9
80. Al-Salmy HS. Inter-strain variability in aldehyde oxidase activity in the mouse. Comp Biochem Physiol C Toxicol Pharmacol 2002;132:341-7 (Pubitemid 34879837)
81. Rosen AS, Fournie P, Darwish M, et al. Zaleplon pharmacokinetics and absolute bioavailability. Biopharm Drug Dispos 1999;20:171-5 (Pubitemid 29137676)